BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 17597290)

  • 21. Prenylation inhibitors stimulate both estrogen receptor alpha transcriptional activity through AF-1 and AF-2 and estrogen receptor beta transcriptional activity.
    Cestac P; Sarrabayrouse G; Médale-Giamarchi C; Rochaix P; Balaguer P; Favre G; Faye JC; Doisneau-Sixou S
    Breast Cancer Res; 2005; 7(1):R60-70. PubMed ID: 15642170
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of oestradiol and tamoxifen on oestrogen receptors-alpha and -beta protein degradation and non-genomic signalling pathways in uterine and breast carcinoma cells.
    Horner-Glister E; Maleki-Dizaji M; Guerin CJ; Johnson SM; Styles J; White IN
    J Mol Endocrinol; 2005 Dec; 35(3):421-32. PubMed ID: 16326830
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Estrogen inhibits the growth of estrogen receptor-negative, but not estrogen receptor-positive, human mammary epithelial cells expressing a recombinant estrogen receptor.
    Zajchowski DA; Sager R; Webster L
    Cancer Res; 1993 Oct; 53(20):5004-11. PubMed ID: 8402691
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estrogen receptor beta increases the efficacy of antiestrogens by effects on apoptosis and cell cycling in breast cancer cells.
    Hodges-Gallagher L; Valentine CD; El Bader S; Kushner PJ
    Breast Cancer Res Treat; 2008 May; 109(2):241-50. PubMed ID: 17638070
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Effects of exogenous ER beta expression on the cell growth properties of MCF-7 breast cancer cell line].
    Zhu JH; Ye QN; Song ST; Jiang ZF; Yan JH; Hao CF; Huang CF
    Zhonghua Zhong Liu Za Zhi; 2006 Feb; 28(2):103-6. PubMed ID: 16750012
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fulvestrant inhibits growth of triple negative breast cancer and synergizes with tamoxifen in ERα positive breast cancer by up-regulation of ERβ.
    Mishra AK; Abrahamsson A; Dabrosin C
    Oncotarget; 2016 Aug; 7(35):56876-56888. PubMed ID: 27486755
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Estrogen and the selective estrogen receptor modulator (SERM) protection against cell death in estrogen receptor alpha and beta expressing U2OS cells.
    Kallio A; Guo T; Lamminen E; Seppänen J; Kangas L; Väänänen HK; Härkönen P
    Mol Cell Endocrinol; 2008 Jul; 289(1-2):38-48. PubMed ID: 18455292
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A metastatic breast tumor cell line, GI-101A, is estrogen receptor positive and responsive to estrogen but resistant to tamoxifen.
    Morrissey JJ; Raney S
    Cell Biol Int; 1998; 22(6):413-9. PubMed ID: 10328849
    [TBL] [Abstract][Full Text] [Related]  

  • 29. P2Y2 receptor-mediated modulation of estrogen-induced proliferation of breast cancer cells.
    Li HJ; Wang LY; Qu HN; Yu LH; Burnstock G; Ni X; Xu M; Ma B
    Mol Cell Endocrinol; 2011 May; 338(1-2):28-37. PubMed ID: 21356271
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of second-line antiestrogen therapy on breast tumor growth after first-line treatment with the aromatase inhibitor letrozole: long-term studies using the intratumoral aromatase postmenopausal breast cancer model.
    Long BJ; Jelovac D; Thiantanawat A; Brodie AM
    Clin Cancer Res; 2002 Jul; 8(7):2378-88. PubMed ID: 12114443
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Up-regulation of PI3K/Akt signaling by 17beta-estradiol through activation of estrogen receptor-alpha, but not estrogen receptor-beta, and stimulates cell growth in breast cancer cells.
    Lee YR; Park J; Yu HN; Kim JS; Youn HJ; Jung SH
    Biochem Biophys Res Commun; 2005 Nov; 336(4):1221-6. PubMed ID: 16169518
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Effects of estrogen receptor beta on proliferation of ovarian clear cell adenocarcinoma ES-2 in vitro and in vivo].
    Zhu J; Feng YJ
    Zhonghua Fu Chan Ke Za Zhi; 2006 Sep; 41(9):588-91. PubMed ID: 17181966
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioassays for estrogenic activity: development and validation of estrogen receptor (ERalpha/ERbeta) and breast cancer proliferation bioassays to measure serum estrogenic activity in clinical studies.
    Li J; Lee L; Gong Y; Shen P; Wong SP; Wise SD; Yong EL
    Assay Drug Dev Technol; 2009 Feb; 7(1):80-9. PubMed ID: 19382890
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibitory effects of estrogen receptor beta on specific hormone-responsive gene expression and association with disease outcome in primary breast cancer.
    Lin CY; Ström A; Li Kong S; Kietz S; Thomsen JS; Tee JB; Vega VB; Miller LD; Smeds J; Bergh J; Gustafsson JA; Liu ET
    Breast Cancer Res; 2007; 9(2):R25. PubMed ID: 17428314
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
    Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
    Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Selenium disrupts estrogen signaling by altering estrogen receptor expression and ligand binding in human breast cancer cells.
    Lee SO; Nadiminty N; Wu XX; Lou W; Dong Y; Ip C; Onate SA; Gao AC
    Cancer Res; 2005 Apr; 65(8):3487-92. PubMed ID: 15833885
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The presence of Estrogen Receptor β modulates the response of breast cancer cells to therapeutic agents.
    Pons DG; Torrens-Mas M; Nadal-Serrano M; Sastre-Serra J; Roca P; Oliver J
    Int J Biochem Cell Biol; 2015 Sep; 66():85-94. PubMed ID: 26232188
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Unliganded estrogen receptor-beta regulation of genes is inhibited by tamoxifen.
    Levy N; Paruthiyil S; Zhao X; Vivar OI; Saunier EF; Griffin C; Tagliaferri M; Cohen I; Speed TP; Leitman DC
    Mol Cell Endocrinol; 2010 Feb; 315(1-2):201-7. PubMed ID: 19744542
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Activity of estradiol and selective estrogen receptor modulators in the mouse N20.1 oligodendrocyte/astrocytes cell line.
    Guzmán CB; Deighton-Collins S; Martinez A; Kleerekoper M; Zhao C; Benjamins JA; Skafar DF
    Neuro Endocrinol Lett; 2005 Oct; 26(5):526-32. PubMed ID: 16264406
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Re-expression of estrogen receptor alpha using a tetracycline-regulated gene expression system induced estrogen-mediated growth inhibition of the MDA-MB-231 breast cancer cell line.
    Barrón-González A; Castro Romero I
    Biochem Cell Biol; 2004 Apr; 82(2):335-42. PubMed ID: 15060629
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.